Dr Daniel Allan Hamstra discusses common adverse reactions in patients with prostate cancer undergoing radiation therapy, including urinary issues and sexual side effects, and explains the potential impact of rectal spacer devices like SpaceOAR in addressing these concerns.
Enzalutamide granted approval in EU for nmHSPC
April 24th 2024The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with leuprolide alone in patients with high-risk biochemically recurrent nmHSPC.